Apogee Therapeutics (APGE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-216.9M
Net Income
-182.1M
Balance Sheet Metrics
Total Assets
754.0M
Total Liabilities
37.2M
Shareholders Equity
716.8M
Debt to Equity
0.05
Cash Flow Metrics
Operating Cash Flow
-159.1M
Free Cash Flow
-172.3M
Revenue & Profitability Trend
Apogee Therapeutics Income Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 216.9M | 93.0M | 30.7M |
| Operating Income | -216.9M | -93.0M | -30.7M |
| Pre-tax Income | -182.1M | -84.0M | -39.8M |
| Income Tax | 18.0K | - | - |
| Net Income | -182.1M | -84.0M | -39.8M |
| EPS (Diluted) | - | -$3.36 | -$1.46 |
Income Statement Trend
Apogee Therapeutics Balance Sheet From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Assets | |||
| Current Assets | 529.7M | 398.4M | 152.1M |
| Non-Current Assets | 224.2M | 3.0M | 0 |
| Total Assets | 754.0M | 401.4M | 152.1M |
| Liabilities | |||
| Current Liabilities | 28.6M | 20.6M | 10.0M |
| Non-Current Liabilities | 8.6M | 933.0K | 0 |
| Total Liabilities | 37.2M | 21.5M | 10.0M |
| Equity | |||
| Total Shareholders Equity | 716.8M | 379.9M | 142.1M |
Balance Sheet Composition
Apogee Therapeutics Cash Flow Statement From 2022 to 2024
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -182.1M | -84.0M | -39.8M |
| Operating Cash Flow | -159.1M | -76.6M | -25.8M |
| Investing Activities | |||
| Capital Expenditures | -1.2M | -167.0K | 0 |
| Investing Cash Flow | -300.5M | -273.9M | 0 |
| Financing Activities | |||
| Dividends Paid | - | - | - |
| Financing Cash Flow | 493.5M | 315.4M | 168.3M |
| Free Cash Flow | -172.3M | -74.9M | -16.4M |
Cash Flow Trend
Apogee Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-11.04
Price to Book
3.63
PEG Ratio
-11.04
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-27.85%
Return on Assets
-19.65%
Financial Health
Current Ratio
15.82
Debt to Equity
1.76
Per Share Data
EPS (TTM)
-$3.61
Book Value per Share
$11.55
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| apge | 2.4B | - | 3.63 | -27.85% | 0.00% | 1.76 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.